Section 232 Pharmaceutical Tariffs 2026: An Importer's Guide to the 100% Duty

On 2 April 2026 the White House signed a proclamation imposing a 100% ad valorem Section 232 tariff on patented pharmaceutical products and their active pharmaceutical ingredients. At GetTransport.com we move a lot of temperature-controlled and high-value pharma freight into the United States, and when a proclamation like this publishes we read it the day it drops, because a duty that doubles the customs value of a shipment changes everything about how we plan a lane. This one leans on Section 232 of the Trade Expansion Act of 1962, the same national-security authority behind the steel and aluminum tariffs, but it points that machinery at medicines for the first time. It runs on two clocks: 31 July 2026 for a first group of 17 named drug companies listed in Annex III of the proclamation, and 29 September 2026 for everyone else. In this guide I will walk you through what the proclamation actually does, who it hits, how to work out whether your own product is in scope, the two-date timeline we are watching, and the checklist we are already running with clients so a 100% duty does not ambush a cold-chain shipment at the port.

What the April 2026 proclamation actually does

The proclamation does not touch the regular tariff schedule the way an ordinary duty change would. It uses Section 232, which lets the president restrict imports the Commerce Department has found to threaten national security, and it applies a 100% ad valorem rate on top of whatever duty a product already carries, unless that existing Column 1 rate is already higher. The stated logic is that heavy reliance on foreign-made medicines and active pharmaceutical ingredients is itself a security risk, so the remedy is a tariff steep enough to pull manufacturing back onshore.

Two things make this different from a routine trade action. First, the rate is blunt: 100% of the customs value, not a few percentage points. Second, the scope is written by tariff code rather than by brand, covering more than 130 specified HTSUS subheadings across chapter 29 (organic chemicals) and chapter 30 (pharmaceutical products). If your product sits in one of those subheadings and meets the patented-drug definition, the code decides your exposure, not the label on the box. The Federal Register notice and the White House proclamation together set out the covered subheadings, and law firms including Crowell & Moring and Foley Hoag published early scope breakdowns that we cross-checked against our own entries.

Who is affected

For us the affected list is wider than just the big brand-name manufacturers everyone pictures. Any importer of record bringing patented finished drugs or bulk APIs into the United States is exposed, and so are the distributors and wholesalers further down the chain. Cold-chain operators feel it indirectly, because a 100% duty raises the stakes on every temperature-sensitive consignment we move, so a delayed or misclassified entry ties up twice as much cash at the border.

Generic-drug importers get a reprieve. The proclamation expressly excludes generic pharmaceuticals and biosimilars, along with the ingredients used to make them, at least for now. A short list of specialty products sits outside the measure too, including orphan drugs, nuclear medicines, plasma-derived therapies, and fertility and cell-and-gene treatments. So a distributor whose book is mostly off-patent volume may find very little of it caught, while a specialty importer of patented biologics could see most of a shipment hit. The split runs along the patent line, not the therapeutic category, which is why we classify product by product rather than by supplier. One caveat we flag to every client is that the generic exclusion is not carved in stone, because the proclamation tells Commerce to report within one year on whether tariffs on generics should be adjusted, so it could be revisited in 2027.

How to work out whether your product is in scope

Here is the sequence we run for a client the moment they ask whether they are exposed. It is four questions, in order, and if you can answer them you know your risk before the first affected entry files. First, is the product patented? Generics and biosimilars fall outside the measure, so an off-patent product is likely clear. Second, which HTSUS chapter and subheading does it classify under? If it is not one of the more than 130 subheadings named across chapters 29 and 30, it is not covered, and classification is worth confirming with a broker rather than guessing. Third, what is the country of origin? The applicable rate turns partly on origin, because several trade partners negotiated caps below the headline 100%: Japan, the European Union, South Korea, Switzerland and Liechtenstein sit at 15%, while the United Kingdom sits at 10% with room to fall to 0% if it finalizes a pricing agreement. Fourth, does the manufacturer behind the product hold a deal with Washington? That last question is the one that catches people out.

Two kinds of deal change the math. A company that signed a Most-Favored-Nation pricing agreement with the Department of Health and Human Services before 2 April 2026, and appears in Annex II of the proclamation, is duty-exempt on the covered products. Separately, a manufacturer with an onshoring plan approved by the Commerce Department pays a reduced 20% rate until 2 April 2030 while it builds domestic capacity, and a company that holds both an approved onshoring plan and an MFN agreement can drop to 0% until 20 January 2029. The Commerce Department published the application process for those onshoring plans on 11 May 2026. WilmerHale and Norton Rose Fulbright both set out how the onshoring-agreement procedures work, and Holland & Knight walked through the Annex II exemption, so we lean on that reading when we help a client trace whether their supplier is covered. The practical point is that your duty can depend on a contract you are not a party to, so you have to ask your manufacturer directly.

The two-date timeline we are watching

The proclamation runs on two deadlines, both counted from the 2 April 2026 signing. The first group, 17 large drug companies named in Annex III, faces the 100% duty from 31 July 2026, which is 120 days out. Every other importer has until 29 September 2026, the 180-day mark. We treat the July date as the real signal even for clients who fall in the September group, because once the first entries file we will see how Customs and Border Protection is actually classifying borderline products.

Landed cost, cold chain, and the bond question

A 100% ad valorem duty does something simple and brutal to landed cost: it roughly doubles the customs-value component of the shipment. On high-value patented drugs, where a single reefer container can carry seven figures of product, that is a very large number to finance at the border. We tell clients to model the duty into landed cost now, not after the first invoice, because a surprise of this size can strand a shipment while finance scrambles.

There is also a bond consequence, the part importers most often underestimate. A customs bond has to cover the duties and fees CBP could assess, so when the duty on a shipment doubles, the bond that was adequate last year may no longer be. Many pharma importers who ran comfortably on a modest continuous bond will need to resize it, and some single-entry importers will cross the threshold where a continuous bond simply makes more sense. We walk clients through the mechanics in our guide to how continuous and single-entry customs bonds work, so read that for the plumbing. This measure is also just one piece of a wider 2026 sectoral push, with the metals tariffs overhauled and a semiconductor Section 232 review underway around July 2026, and our map of the Section 232 tariffs tracks those actions in one place.

A preparation checklist for pharma importers

Here is the short version of what we are doing with clients right now, and none of it needs the final CBP guidance to be published first.

• Classify product by product: confirm the HTSUS subheading against the more than 130 covered codes in chapters 29 and 30, because the code decides exposure, not the marketing name.
• Check the patent status of every SKU. Generics and biosimilars are excluded for now, as are orphan drugs, nuclear medicines, plasma-derived therapies and fertility and cell-and-gene treatments.
• Ask your manufacturer two blunt questions: does it hold an HHS Most-Favored-Nation agreement listed in Annex II, and does it have a Commerce-approved onshoring plan that would cut the rate to 20% or even 0%? Your rate can depend on either one.
• Resize your customs bond with your surety ahead of the July and September dates, because a doubled duty can push your required coverage well past its old level.
• Model the duty into landed cost and cash flow now, especially on high-value cold-chain consignments where the financing hit is largest, and check your country of origin against the 15% and 10% caps.
• Watch the 31 July 2026 entries even if you fall in the September group, so you learn how CBP is classifying borderline products before your own deadline arrives.

Frequently asked questions

When do the pharmaceutical Section 232 tariffs take effect?

There are two dates, both counted from the 2 April 2026 proclamation. The 17 named large drug companies in Annex III face the 100% duty from 31 July 2026, the 120-day mark, and all other importers from 29 September 2026, the 180-day mark. CBP can issue guidance sooner, so we plan against the earlier July date.

Which products are covered, and which are exempt?

The measure covers patented finished drugs and their active pharmaceutical ingredients across more than 130 HTSUS subheadings in chapters 29 and 30. Generic pharmaceuticals and biosimilars are expressly excluded for now, as are orphan drugs, nuclear medicines, plasma-derived therapies and fertility and cell-and-gene treatments. Products from a manufacturer that holds a Health and Human Services Most-Favored-Nation agreement in Annex II are duty-exempt, and a manufacturer with a Commerce-approved onshoring plan pays a reduced 20% rate until 2 April 2030.

How much will the tariff add to my landed cost?

The rate is 100% ad valorem, so it roughly doubles the customs-value portion of a covered shipment on top of any existing duty, unless that existing rate is already higher. On high-value patented drugs that is a large sum to finance at the border, which is why we model it into landed cost before the first affected entry rather than after it. If your country of origin is Japan, the EU, South Korea, Switzerland, Liechtenstein or the UK, check the lower negotiated cap first.

Do I need a bigger customs bond?

Very likely, if you import covered products. A bond has to cover the duties and fees CBP could assess, so a duty that doubles can push your required coverage past what an older continuous bond allowed. We size this with the surety before the deadline. For how to choose between continuous and single-entry coverage, see our customs bonds guide rather than this article.